What You Need to Know
• The U.S. Food and Drug Administration approved daraxonrasib, branded as Rasonque, for pancreatic cancer treatment.
• Clinical trials showed that patients taking daraxonrasib had an average survival time of 13.2 months.
• Approximately 67,000 individuals in the U.S. are diagnosed with pancreatic cancer each year, which has a high mortality rate.
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, a new treatment for pancreatic cancer, which has shown promising results in clinical trials. The drug, manufactured by Revolution Medicines and marketed under the brand name Rasonque, nearly doubled the average survival time for patients, increasing it from 6.6 months with chemotherapy to 13.2 months. The FDA described this treatment as a “critical new option” for patients facing this challenging cancer, which affects about 67,000 people annually in the United States. Daraxonrasib works by targeting the mutated KRAS gene, present in over 90% of pancreatic tumors, and the approval was expedited due to its significant impact on a condition with historically limited treatment options.
Why It Matters
Pancreatic cancer is known for its late diagnosis and high mortality rate, with more than half of diagnosed patients dying within three months. The FDA’s approval of daraxonrasib represents a significant advancement in treatment options for this aggressive cancer type. In 2025, the drug received a “Breakthrough Therapy” designation, highlighting its potential to address unmet medical needs. This approval may lead to improved outcomes for patients who previously had limited treatment alternatives.
Read the Full Story →
